Petosemtamab (MCLA-158)

Date Publication
Sep 14, 2024
Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1–positive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase 3 trial
Presented on September 14, 2024
Sep 14, 2024
Petosemtamab compared with investigator’s choice monotherapy in previously treated patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase 3 trial
Presented on September 14, 2024
Jun 03, 2024
ORAL PRESENTATION:
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study
Presented on June 3, 2024
Apr 17, 2023
MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA)
Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Apr 17, 2023
ORAL PRESENTATION:
Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)
Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Apr 25, 2022
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
Bram Herpers, Berina Eppink, Mark I. James, Carme Cortina, Adrià Cañellas-Socias, Sylvia F. Boj, Xavier Hernando-Momblona, Dominik Glodzik, Rob C. Roovers, Marc van de Wetering, Carina Bartelink Clements, Vanessa Zondag van der Zande, Jara García Mateos, Kuan Yan, Lucia Salinaro, Abdul Basmeleh, Szabolcs Fatrai, David Maussang, Jeroen J Lammerts van Bueren, Irene Chicote, Garazi Serna, Laia Cabellos, Lorena Ramírez, Paolo Nuciforo, Ramon Salazar, Cristina Santos, Alberto Villanueva, Camille Stephan-Otto-Attolini, Elena Sancho, Hector G. Palmer, Josep Tabernero, Michael R. Stratton, John de Kruif, Ton Logtenberg, Hans Clevers, Leo S. Price, Robert Vries, Eduard Batlle, Mark Throsby Nature Cancer DOI 10.1038/s43018-022-00359-0
Oct 07, 2021
Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma
Presented at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (2021)
Jan 15, 2021
Phase I dose escalation study of MCLA-158, a first in class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC)
Poster presented at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
Apr 01, 2017
Identification and characterisation of MCLA-158 as an anti-EGFRxLGR5 bispecific antibody that potently inhibits patient-derived CRC organoid growth
Rob C. Roovers1, Bram Herpers2, Mark James3, Berina Eppink1, Carme Cortina3, David Maussang-Detaille1, Ingrid Kolfschoten1, Sylvia F. Boy4, Marc van de Wetering4, Wim de Lau5, Robert Doornbos1, Carina Clements1, Abdul Basmeleh1, Willem Bartelink1, Vanessa Zondag van de Zande1, Kuan Yan2, Lucia Salinaro2, Lex Bakker1, John de Kruif1, Hans Clevers5, Robert Vries4, Eduard Batlle3, Leo Price2 and Mark Throsby1. 1Merus NV, Utrecht, Netherlands; 2OcellO BV, Leiden, Netherlands; 3IRB Barcelona, Spain; 4HUB, Utrecht, Netherlands; 5The Hubrecht Institute, Utrecht, Netherlands. Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.
Nov 04, 2015
Generation of Wnt- and mitogenic receptor binding bispecific antibodies to target cancer stem cells
Berina Eppink1, Rob Roovers1, Bram Herpers2, Wim de Lau3, Carina Clements1, Vanessa Zondag van der Zande1, Abdul Basmeleh1, Willem Bartelink1, Marc van de Wetering3,4, Robert Vries3,4, Leo Price2, John de Kruif1, and Mark Throsby1. 1Merus BV Utrecht, Netherlands; 2OcellO BV, Leiden, Netherlands; 3Hubrecht Institute, Utrecht, Netherlands; 4HUB, Utrecht, Netherlands. Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA.

Zenocutuzumab (MCLA-128)

Date Publication
Apr 08, 2024
Zenocutuzumab, a HER2 × HER3 bispecific antibody, is effective in cancer models with high NRG1 expression
Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Feb 14, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
Dong-Wan Kim‡, Alison M Schram‡, Antoine Hollebecque, Kazumi Nishino, Teresa Macarulla, Sun Young Rha, Michaël Duruisseaux, Stephen V Liu, Mohammed Najeeb Al Hallak, Kumiko Umemoto, Claas Wesseler, James M Cleary, Christoph Springfeld, Cindy Neuzillet, Andrew Joe, Shekeab Jauhari, Jim Ford & Koichi Goto Future Medicine doi: 10.2217/fon-2023-0824
Dec 02, 2023
Durable efficacy of zenocutuzumab, a HER2 × HER3 bispecific antibody, in advanced NRG1 fusion–positive (NRG1+) non-small cell lung cancer (NSCLC)
Presented at the European Society for Medical Oncology (ESMO) Asia Congress 2023
Oct 21, 2023
Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presented at the European Society for Medical Oncology (ESMO) Congress 2023
Oct 20, 2023
Durable efficacy of zenocutuzumab, a HER2 × HER3 bispecific antibody, in advanced NRG1 fusion–positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Poster presented at the European Society for Medical Oncology (ESMO) Congress 2023
Aug 18, 2022
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor
Elisa Fontana , MD, PhD; Gonzalo Torga , MD; Raluca Fostea , MD; Susan Cleator, MD; Ernesto Wasserman, MD; Anastasia Murat, PhD; and Hendrik-Tobias Arkenau , MD, PhD DOI: 10.1200/PO.21.00446 JCO Precision Oncology no. 6 (2022) e2100446. Published online August 17, 2022.
Jun 05, 2022
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) cancers
Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Feb 08, 2022
Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
Alison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J Sisso, Marissa S Mattar, Allan J.W Lui, Morana Vojnic, Sara H Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, Marie N O'Connor, Cecile A. W Geuijen, Ron CJ Schackmann, Jeroen J. Lammerts van Bueren, Ernesto Wasserman, Elisa de Stanchina, Eileen M O'Reilly, Marc Ladanyi, Alexander Drilon and Romel Somwar Cancer Discovery DOI: 10.1158/2159-8290.CD-21-1119
Dec 10, 2021
Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients with HER2 positive/amplified (HER2+) metastatic breast cancer who progressed on previous anti-HER2 ADCs
Presented at the San Antonio Breast Cancer Symposium (SABCS) 2021
Oct 07, 2021
Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions
Presented at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (2021)
Jun 04, 2021
Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions
Presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Apr 10, 2021
The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
Poster presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Apr 10, 2021
Zenocutuzumab, an antibody that can overcome HER3 mediated NRG1 signaling in tumor cells by docking on HER2.
Poster presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Jan 28, 2021
Phase 2 study of Zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors
Presented at the IASLC 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer
May 29, 2020
NRG1 fusion-driven cancers: A systematic literature review and meta-analysis.
Viktoriya Stalbovskaya, Ernesto Wasserman, Jon Fryzek, Lauren C Bylsma, and L. Andres Sirulnik.
Journal of Clinical Oncology (2020)
May 29, 2020
A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
TiP poster presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting
May 29, 2020
Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer patients with ET-resistant disease who had progressed on a cyclin-dependent kinase (CDK) 4/6 inhibitor
Poster presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting
May 29, 2020
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab and vinorelbine in HER2-amplified metastatic breast cancer patients (MBC) who had progressed on anti-HER2 antibody drug conjugates (ADCs)
Poster presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting
Jan 31, 2020
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
Aurelia H. M. de Vries Schultink, Kees Bol, Robert P. Doornbos, Anastasia Murat, Ernesto Wasserman, Thomas P. C. Dorlo, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema. Clinical Pharmacokinetics, (2020).  
Oct 27, 2019
Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Alison M Schram1, Eileen M O'Reilly1, Romel Somwar1, Ryma Benayed1, Sara Shameem1, Thrusha Chauhan1, Jean Torrisi1, Jim Ford2, David Maussang2, Ernesto Wasserman2, Marc Ladanyi1, David M Hyman1, L Andres Sirulnik2, Alexander E Drilon1. 1Memorial Sloan Kettering, NY, USA; 2Merus N.V., Utrecht, Netherlands. Poster presented at the AACR-NCI-EORTC 2019 Congress, Boston, MA, USA.
Oct 27, 2019
Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Alison M Schram1, Eileen M O'Reilly1, Romel Somwar1, Ryma Benayed1, Sara Shameem1, Thrusha Chauhan1, Jean Torrisi1, Jim Ford2, David Maussang2, Ernesto Wasserman2, Marc Ladanyi1, David M Hyman1, L Andres Sirulnik2, Alexander E Drilon1. 1Memorial Sloan Kettering, NY, USA; 2Merus N.V., Utrecht, Netherlands. Poster presented at the AACR-NCI-EORTC 2019 Congress, Boston, MA, USA.
Sep 29, 2019
A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
AM Schram1, A Drilon1, T Macarulla Mercade2, EM O'Reilly1, J Rodon3, B Wolpin4, S-HI Ou5, D-W Kim6, JCH Yang7, YC Lam8, A Varga9, AJ de Langen10, P Witteveen11, V Boni12, G Cerea13, M Duruisseaux14, SV Liu15, E Wasserman16, DM Hyman1, J Tabernero2. 1Memorial Sloan Kettering/Weill Cornell Medical College, NY, USA; 2Vall d'Hebron University Hospital/VHIO, Barcelona, Spain; 3MD Anderson Cancer Center, TX, USA; 4Dana-Farber Cancer Institute, MA, USA; 5University of California Irvine, CA, USA; 6Seoul National University Hospital, Seoul, Republic of Korea ; 7National Taiwan University Cancer Center/Hospital, Taipei, Taiwan; 8National Cancer Centre Singapore, Singapore; 9Gustave Roussy, Villejuif, France; 10Netherlands Cancer Institute, Netherlands, 11UMC Utrecht Cancer Center, Netherlands; 12START Madrid-CIOCC/University Hospital Sanchinarro, Madrid, Spain; 13Niguarda Cancer Center, Ospedale Niguarda/Università degli Studi di Milano, Italy; 14Hôpital Louis Pradel-Hospices Civils de Lyon, France; 15Lombardi Cancer Center Georgetown University, Washington, USA; 16Merus N.V., Utrecht, Netherlands. Poster presented at the European Society for Medical Oncology (ESMO) 2019 Congress, Barcelona, Spain.
Oct 21, 2018
Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended Phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)
Maria Alsina1, Andrea Varga2, Alessio Amatu3, Jan H.M. Schellens4, Els Witteveen5, Valentina Boni6, Victor Moreno7, Paolo Nuciforo1, Aurelia de Vries Schultink4, Kees Bol8, Afrodite Lourbakos8, Marina Magin Ferrer8, and Ernesto Wasserman8. 1Vall d'Hebron University Hospital, Barcelona, Spain; 2DITEP, Gustave Roussy, Villejuif, France; 3Niguarda Hospital, Milan, Italy; 4Netherlands Cancer Institute, Amsterdam, Netherlands; 5University Medical Center Utrecht, Netherlands; 6START CIOCC, Madrid, Spain; 7START -  FJD, Madrid, Spain; 8Merus NV, Utrecht, Netherlands. Poster presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany.
May 14, 2018
Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade
Cecile A.W. Geuijen, Camilla De Nardis, David Maussang, Eric Rovers, Tristan Gallenne, Linda J.A. Hendriks, Therese Visser, Roy Nijhuis, Ton Logtenberg, John de Kruif, Piet Gros, and Mark Throsby. Cancer Cell, 33, 922-936 (2018).
May 05, 2018
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker, Kees Bol, Mark Throsby, Cecile Geuijen, David Maussang, Jan H. M. Schellens, Jos H. Beijnen, and Alwin D. R. Huitema. Investigational New Drugs, 36, 1006-1015 (2018).
Jun 02, 2017
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3; final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC)
Maria Alsina1, Valentina Boni2, Aurelia de Vries Schultink3, Victor Moreno4, Kees Bol5, Martine Westendorp5, L. Andres Sirulnik5, Josep Tabernero1, and Emiliano Calvo2.1Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; 2START Madrid CIOCC, Hospital HM Universitario Sanchinarro, Madrid, Spain; 3Netherlands Cancer Institute, Amsterdam, Netherlands; 4START - FJD, Madrid, Spain; 5Merus NV, Utrecht, Netherlands. Poster presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, USA.
Apr 01, 2017
The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis
David Maussang1, Camilla De Nardis2, Linda Hendriks1, Carina Bartelink-Clements1, Nellie Nieuwenhuizen1, Eric Rovers1, Tristan Gallenne1, Robert Doornbos1, Lex Bakker1, Ton Logtenberg1, John de Kruif1, Piet Gros2, Cecile Geuijen1, and Mark Throsby1.1Merus NV, Utrecht, Netherlands; 2Utrecht University, Netherlands. Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.
Apr 22, 2015
Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2:HER3 heterodimer
Cecile Geuijen, Eric Rovers, Tristan Gallenne, David Maussang-Detaille, Arjen Kramer, Nellie Nieuwenhuizen, Katinka van Zoest, Roy Nijhuis, Therese Visser, Renate den Blanken-Smit, Abdul Basmeleh , Willem Bartelink, Vanessa Zondag-van der Zande, Carina Clements, Linda Kaldenberg, Pieter Fokko van Loo, Rob Roovers, Leo Price, Stefan Braam, Robert Doornbos, Setareh van Driel Shamsili, Lex Bakker, Ton Logtenberg, John de Kruif, Mark Throsby. Poster presented at the American Association for Cancer Research (AACR) 2015 Annual Meeting, Philadelphia, Pennsylvania, USA.

MCLA-129

Date Publication
Jun 03, 2024
Efficacy and Safety of MCLA-129, an Anti-EGFR/c-MET Bispecific Antibody, in Non-Small Cell Lung Cancer (NSCLC) With Hepatocyte Growth Factor Receptor (c-MET) Exon 14 Skipping Mutations (METex14)
Poster presented on June 3, 2024
Dec 02, 2023
ORAL PRESENTATION:
Efficacy and safety of MCLA-129, an EGFR x c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
Presented at the European Society for Medical Oncology (ESMO) Asia Congress 2023
Dec 02, 2023
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell carcinoma (HNSCC)
Presented at the European Society for Medical Oncology (ESMO) Asia Congress 2023
Apr 18, 2023
Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab
Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Oct 26, 2022
MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study
Presented at EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics (2022)
Apr 10, 2022
Mechanism of action of MCLA-129, a bispecific antibody that targets EGFR and c-MET and impairs growth of EGFR exon 20 insertion mutant non-small cell lung cancer
Poster presented at the American Association for Cancer Research Annual Meeting 2022
Apr 10, 2021
The bispecific antibody MCLA-129 impairs NSCLC tumor growth by targeting EGFR and c-MET, inhibiting ligand-induced signaling and promoting ADCC and ADCP
Poster presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Oct 29, 2019
Preclinical evaluation of MCLA-129: a bispecific antibody targeting c-MET and EGFR
Cecile Geuijen1, Mario di Matteo2,3, Sarah Trusso Cafarello2,3, Tristan Gallenne1, Roy Nijhuis1, Therese Visser1, Willem Bartelink1, Carina Bartelink-Clements1, Vanessa Zondag-van der Zande1, Eric Rovers1, Karin de Cortie1, Linda Kaldenberg-Hendriks1, Berina Eppink1, Rinse Klooster1, John de Kruif1, Massimiliano Mazzone2,3, Mark Throsby1. 1Merus N.V. Utrecht, The Netherlands; 2Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium; 3Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, Department of Oncology, KU Leuven, Belgium. Poster presented at the AACR-NCI-EORTC 2019 Congress, Boston, MA, USA.

MCLA-145

Date Publication
Jun 02, 2024
ORAL PRESENTATION:
Phase 1 study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab
Presented on June 2, 2024
Dec 06, 2021
Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors
Presented at ESMO Immuno-Oncology (ESMO IO) Congress 2021
Jul 21, 2021
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Cecile Geuijen, Paul Tacken, Liang-Chuan Wang, Rinse Klooster, Pieter Fokko van Loo, Jing Zhou, Arpita Mondal, Yao-bin Liu, Arjen Kramer, Thomas Condamine, Alla Volgina, Linda J. A. Hendriks, Hans van der Maaden, Eric Rovers, Steef Engels, Floris Fransen, Renate den Blanken-Smit, Vanessa Zondag-van der Zande, Abdul Basmeleh, Willem Bartelink, Ashwini Kulkarni, Wilfred Marissen, Cheng-Yen Huang, Leslie Hall, Shane Harvey, Soyeon Kim, Marina Martinez, Shaun O'Brien, Edmund Moon, Steven Albelda, Chrysi Kanellopoulou, Shaun Stewart, Horacio Nastri, Alexander B. H. Bakker, Peggy Scherle, Ton Logtenberg, Gregory Hollis, John de Kruif, Reid Huber, Patrick A. Mayes & Mark Throsby Nature Communications volume 12, Article number: 4445 (2021)
Nov 09, 2020
MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells
Poster presented at the Society for Immunotherapy of Cancer's (SITC) 2020 Annual Meeting.
Nov 09, 2020
MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that does not show signs of peripheral toxicity in preclinical models
Poster presented at the Society for Immunotherapy of Cancer's (SITC) 2020 Annual Meeting.
Mar 31, 2019
An unbiased screen identifies a CD137xPD-L1 bispecific IgG1 antibody with unique T cell activation and binding properties
Cecile A. Geuijen1, Paul Tacken1, Rinse Klooster1, Horacio Nastri2, Shaun Stewart2, Jing Zhou2, Steve Wang2, Cheng-Yen Huang2, Arjen Kramer1, Linda Kaldenberg-Hendriks1, John de Kruif1, Renate den Blanken-Smit1, Vanessa Zondag-van de Zande1, Abdul Basmeleh1, Willem Bartelink1, Patrick Mayes2, Gregory Hollis2, Reid Huber2, Mark Throsby1. 1Merus NV, Utrecht, Netherlands; 2Incyte Corporation, Wilmington, DE. Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.
Mar 31, 2019
A bispecific Fc-silenced IgG1 antibody (MCLA-145) requires PD-L1 binding to activate CD137
Patrick Mayes1, Paul Tacken2, Steve Wang1, Pieter-Fokko van Loo2, Thomas Condamine1, Hans van der Maaden2, Eric Rovers2, Steef Engels2, Floris Fransen2, Ashwini Kulkarni1, Yao-bin Liu1, Arpita Mondal1, Leslie Hall1, Soyeon Kim3, Marina Martinez3, Shaun O'Brien3, Edmund Moon3, Steven Albelda3, Peggy Scherle1, Gregory Hollis1, Reid Huber1, Mark Throsby2, Cecile A. Geuijen2. 1Incyte Corporation, Wilmington, DE; 2Merus NV, Utrecht, Netherlands; 3University of Pennsylvania, Philadelphia. Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.

CD3 T Cell Engagers

Date Publication
Jun 12, 2020
Update from the ongoing phase I multinational study of MCLA-117, a bispecific CLEC12A x CD3 T-cell engager, in patients with acute myelogenous leukemia
Poster presented at the virtual edition of the European Hematology Association (EHA) 2020 Annual Congress.
Jun 12, 2020
T cell engaging bispecific antibodies generated from a novel, large and diverse CD3 panel demonstrate functionality uncoupled from affinity
Poster presented at the virtual edition of the European Hematology Association (EHA) 2020 Annual Congress.
Jul 09, 2019
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis
Pieter Fokko van Loo, Basav N. Hangalapura, Soley Thordardottir, John D. Gibbins, Henrike Veninga, Linda J. A. Hendriks, Arjen Kramer, Rob C. Roovers, Marij Leenders, John de Kruif, Robert P. Doornbos, Andres Sirulnik, Mark Throsby, Ton Logtenberg, Harry Dolstra & Alexander B. H. Bakker. Expert Opinion on Biological Therapy, 19, 721-733 (2019).
Nov 09, 2016
MCLA-117, a CLEC12AxCD3 bispecific IgG targeting a leukemic stem cell antigen, induces T cell mediated AML blast lysis
Pieter Fokko van Loo1, Henrike Veninga1, Harry Dolstra2, and Lex Bakker1. 1Merus NV, Utrecht, Netherlands; 2Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands. Poster presented at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting, National Harbor, MD, USA.

Merus Platform Technology

Date Publication
May 14, 2024
ADClonicsTM Bispecific ADC Program
Presented at PEGS Boston Summit
Jun 27, 2017
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1
Camilla De Nardis*, Linda J.A. Hendriks*, Emilie Poirier, Tudor Arvinte, Piet Gros, Alexander B.H. Bakker, and John de Kruif. Journal of Biological Chemistry, 292, 14706-14717 (2017).
Sep 26, 2016
Generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity
Rinse Klooster, Cecile Geuijen, Renate den Blanken-Smit, Mireille Koenders, Annette Wensink, Eric Rovers, Hans van der Maaden, Steef Engels, Tristan Gallenne, Therese Visser, Carina Bartelink-Clements, Katinka van Zoest, Roy Nijhuis, Abdul Basmeleh, Willem Bartelink, Vanessa Zondag-van der Zande, Arjen Kramer, Linda Kaldenberg, Berina Eppink, Rob Roovers, Paul Tacken, Lex Bakker, Pieter Fokko van Loo, John de Kruif, and Mark Throsby. Poster presented at the International Congress on Immunotherapies in Cancer (ICIC) 2016 Annual Meeting, New York, NY, USA.
Nov 11, 2013
Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry
Natalie J. Thompson, Linda J.A. Hendriks, John de Kruif, Mark Throsby, and Albert J.R. Heck. mAbs, 6, 197-203 (2013).
Aug 10, 2012
Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry
Sara Rosati, Natalie J. Thompson, Arjan Barendregt, Linda J. A. Hendriks, Alexander B. H. Bakker, John de Kruif, Mark Throsby, Esther van Duijn, and Albert J. R. Heck. Analytical Chemistry, 84, 7227-7232 (2012).
Jun 21, 2010
Generation of stable cell clones expressing mixtures of human antibodies
John de Kruif, Arjen Kramer, Roy Nijhuis, Vanessa van der Zande, Renate den Blanken, Carina Clements, Therese Visser, Rob Keehnen, Marcel den Hartog, Mark Throsby, and Ton Logtenberg. Biotechnology and Bioengineering, 106, 741-750 (2010).
Apr 03, 2009
Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous VH genes
John de Kruif, Arjen Kramer, Therèse Visser, Carina Clements, Roy Nijhuis, Freek Cox, Vanessa van der Zande, Renate Smit, Daniel Pinto, Mark Throsby, and Ton Logtenberg. Journal of Molecular Biology, 387, 548-558 (2009).